A postsurgical chemotherapy regimen of Roche’s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and chemotherapy cut the risk of death by 28 percent compared to Herceptin and chemo alone in patients with lymph node-positive, hormone receptor-positive (HER-2) breast cancer.
Source: Drug Industry Daily